Johnson & Johnson Accelerates Growth and Impact in Q2 2026
Johnson & Johnson recently reported its second quarter 2026 earnings, showcasing a strong performance that sets the company on track to meet its target of over $100 billion in annual revenue for the first time in its 140-year history. During the quarterly call, Chairman and CEO Joaquin Duato highlighted the company's growth drivers and business performance, emphasizing the unique combination of scientific expertise, scale, and disciplined execution that has driven success across oncology, immunology, neuroscience, cardiovascular surgery ambition, and more.
Operational sales growth reached 5.6% in Q2, with double-digit growth excluding STELARA. This achievement demonstrates Johnson & Johnson's ability to adapt and innovate in a rapidly evolving market, capitalizing on emerging trends and technologies to stay ahead of the competition. The company has consistently delivered strong results across its diverse portfolio of products and platforms, each generating over $1 billion in annual sales.
Johnson & Johnson's new launches have also made significant contributions to Q2 performance, with ICOTYDE, INLEXZO, and RYBREVANT showing promising early momentum. The unmet need for patients seeking first-line systemic treatment has been underscored by the rapid uptake of ICOTYDE, which has seen over 10,000 patients initiate therapy since its launch. This success is a testament to Johnson & Johnson's commitment to delivering innovative solutions that meet the evolving needs of healthcare providers and patients alike.
Within Innovative Medicine, operational sales growth reached 6.8% in Q2, with eight brands achieving double-digit growth. In oncology, Johnson & Johnson remains committed to transforming patient outcomes, aiming to become the number one oncology company by 2030. Sales are projected to exceed $50 billion, driven by strong performance from leading products such as DARZALEX. This foundational treatment for multiple myeloma has consistently delivered sales of over $4 billion and continues to grow at a rate close to 18%.
The breadth and depth of Johnson & Johnson's portfolio are evident in its leadership across every line of therapy in multiple myeloma, with 80% of patients receiving one or more of the company's medicines during their treatment journey. This comprehensive approach underscores the company's dedication to delivering value to patients, caregivers, and the wider healthcare ecosystem.
With Q2 sales exceeding $25 billion, Johnson & Johnson is well-positioned to meet its ambitious target for 2026. The company's ability to balance innovation with disciplined execution has driven success across multiple therapeutic areas, positioning it as a leader in the global healthcare industry.
